Teva Pharmaceutical Industries Ltd. Press Releases https://ir.tevapharm.com/generated by Q4Thu, 16 Jul 2026 21:16:26 -0400Copyright Q4 Inc. All rights reserved.Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9dfdf972-64d7-4515-9b37-50e4a4d78b48https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-and-Polpharma-Biologics-Announce-Global-Licensing-Agreement-for-a-Biosimilar-Candidate-to-Ocrevus-ocrelizumab-for-Multiple-Sclerosis/default.aspxThu, 09 Jul 2026 08:30:00 -0400Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results01ca9f7b-9d21-4b39-8eb8-ccd78f8c857ehttps://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Advance-Its-Anti-IL-15-Antibody-Designed-for-Quarterly-Dosing-Into-Phase-2b-Development-in-Vitiligo-Following-Encouraging-Phase-1b-Results/default.aspxTue, 07 Jul 2026 07:00:00 -0400Teva Releases Q2 2026 Aide Memoire8b782ed7-a3ff-4bda-9471-90b594f29c80https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Releases-Q2-2026-Aide-Memoire/default.aspxThu, 18 Jun 2026 17:00:00 -0400Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndromef8ad4f9b-8cb9-4e0d-8cd6-848a6f193ae8https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Submits-NDA-for-Ecopipam-a-First-in-Class-Investigational-Therapy-for-Pediatric-Tourette-Syndrome/default.aspxThu, 18 Jun 2026 16:56:00 -0400Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome50cfe922-32ff-4fac-a0bf-e8d2b330e8b3https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Submits-NDA-for-Ecopipam-a-First-in-Class-Investigational-Therapy-for-Pediatric-Tourette-Syndrome/default.aspxThu, 18 Jun 2026 16:56:00 -0400Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET66daa6a8-0325-4599-a30e-128430a52827https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-to-Host-Conference-Call-to-Discuss-Second-Quarter-2026-Financial-Results-on-July-29-2026-at-8-a-m--ET/default.aspxThu, 18 Jun 2026 16:30:00 -0400Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy c1d1fb83-74cb-4a5e-918e-da5ad87b9e3bhttps://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Closes-Acquisition-of-Emalex-Biosciences-Strengthening-Late-Stage-Neuroscience-Pipeline-and-Advancing-Pivot-to-Growth-Strategy/default.aspxWed, 10 Jun 2026 12:03:00 -0400Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care9aa7f98c-1b93-4199-9ca6-2496b29fcedchttps://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Tevas-Data-on-AUSTEDO-deutetrabenazine-tablets-and-AUSTEDO-XR-deutetrabenazine-extended-release-tablets-Highlight-Long-Term-Advances-in-Tardive-Dyskinesia-Treatment-and-Care/default.aspxMon, 08 Jun 2026 08:00:00 -0400Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Choreab7b3c0da-46d3-4fd3-9bb1-f64862b9f635https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Presents-New-Data-on-AUSTEDO-deutetrabenazine-tablets-and-AUSTEDO-XR-deutetrabenazine-extended-release-tablets-that-Show-Patient--and-Caregiver-Reported-Improvements-in-Huntingtons-Disease-Chorea/default.aspxFri, 05 Jun 2026 11:30:00 -0400Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®77ae54ab-bc27-4d80-ade1-970bf5bb2f5ahttps://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/Teva-Expands-European-biosimilars-portfolio-with-launch-ofAHZANTIVEaflibercept-biosimilar-to-Eylea/default.aspxThu, 04 Jun 2026 08:30:00 -0400